Levonorgestrel spiraal versus progesteron oraal voor de behandeling van hyperplasie zonder atypie van het endometrium.

Levonorgestrel spiraal versus progesteron oraal voor de behandeling van hyperplasie zonder atypie van het endometrium. - HYPROLEV-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36959

Enrollment

Registered

2009-01-07

Start date

2011-04-11

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abnormal endometrial tissue precancer leasion of woomb

Interventions

One group will be treated bij oral progesteron and the oter group will get a levonorgestrel-IUD.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: endometrial hyperplasia (simple and complex), Dutch language

Exclusion criteria

Exclusion criteria: endometrial cancer, hyperplasia with atypie, history of hyperplasia, contra-indication for treatment with progesteron, biopt not possible for any reason

Design outcomes

Primary

Measure	Time frame
endometrial atrofy after treatment	—

Secondary

Measure	Time frame
less side-effects in the study-group than the control-group	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)